[Part I - Financial Information](index=5&type=section&id=Part%20I%20-%20Financial%20Information) [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) The unaudited condensed consolidated financial statements for June 30, 2025, reflect significant changes driven by the June 2025 IPO, including a substantial increase in cash, a shift from shareholders' deficit to positive equity, and strong revenue growth despite continued net losses - **Net IPO proceeds of $459.5 million** from 23,529,412 shares at $21.00, plus **$68.9 million** from over-allotment[34](index=34&type=chunk) - All outstanding redeemable convertible preferred stock converted into **211,378,638 common shares** upon IPO[36](index=36&type=chunk) - A **one-for-four reverse stock split** of common stock was effective June 1, 2025, with all share and per-share data retroactively adjusted[33](index=33&type=chunk) [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet as of June 30, 2025, reflects significant financial improvement post-IPO, with cash increasing to **$720.4 million** and a **$2.5 billion shareholders' deficit** converting to **$452.9 million positive equity** Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash, cash equivalents, and restricted cash | $720,444 | $65,442 | | Total current assets | $833,319 | $215,729 | | **Total assets** | **$955,058** | **$343,734** | | **Liabilities & Equity** | | | | Total current liabilities | $90,180 | $165,423 | | Total liabilities | $502,154 | $620,921 | | Redeemable convertible preferred stock | $0 | $2,221,651 | | Total shareholders' equity (deficit) | $452,904 | $(2,498,838) | | **Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit)** | **$955,058** | **$343,734** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For Q2 2025, total revenue increased **81.3% year-over-year to $181.4 million**, but the company reported a net loss of **$71.8 million**, slightly higher than Q2 2024, due to increased operating and other IPO-related expenses Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $181,398 | $100,049 | $302,314 | $180,727 | | Loss from Operations | $(17,989) | $(67,011) | $(75,940) | $(159,234) | | Net Loss | $(71,790) | $(66,186) | $(174,370) | $(177,214) | | Net Loss per Share | $(7.97) | $(2.54) | $(12.80) | $(6.34) | - A **$384.4 million deemed dividend** on Series D preferred stock significantly increased net loss attributable to common shareholders for the three and six months ended June 30, 2025[14](index=14&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, net cash used in operating activities improved to **$24.1 million**, while financing activities provided **$682.7 million**, primarily from the IPO, resulting in a **$654.7 million net increase in cash** Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(24,050) | $(136,851) | | Net cash provided by (used in) investing activities | $(4,075) | $57,050 | | Net cash provided by financing activities | $682,687 | $199,979 | | **Net increase in cash, cash equivalents, and restricted cash** | **$654,659** | **$120,191** | [Notes to Condensed Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies and significant financial events, including the company's business as an AI TechBio and precision medicine firm, pre-IPO financing, IPO specifics, revenue recognition, and long-term debt, including a **$400 million term loan** - Revenue is primarily derived from **Molecular profiling services** (MI Profile and Caris Assure) and **Pharma research and development services**[44](index=44&type=chunk) - In April 2025, the company raised **$167.7 million** through private financing, including convertible notes, warrants, and Series E and F preferred stock[29](index=29&type=chunk) - As of June 30, 2025, a **$400 million term loan** was outstanding, due January 2028, with an interest rate of **10.8%**[169](index=169&type=chunk)[171](index=171&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=53&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management highlights the company's strong revenue growth driven by molecular profiling solutions and increased clinical case volumes, achieving positive Adjusted EBITDA in Q2 2025, with IPO proceeds significantly strengthening liquidity for future operations and R&D investments - Global annual clinical case volume grew **26% year-over-year** through Q2 2025[203](index=203&type=chunk) - The launches of **Caris Assure** (Q1 2024) and **MI Cancer Seek** (Q1 2025) are anticipated as significant growth drivers[203](index=203&type=chunk) Key Financial Metrics (in millions) | Metric | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $181.4 | $100.0 | $302.3 | $180.7 | | Net Loss | $(71.8) | $(66.2) | $(174.4) | $(177.2) | | Adjusted EBITDA | $16.7 | $(50.9) | $(19.5) | $(121.0) | | Free Cash Flow | N/A | N/A | $(28.1) | $(141.2) | [Results of Operations](index=59&type=section&id=Results%20of%20Operations) Q2 2025 revenue increased **81.3% year-over-year to $181.4 million**, primarily from **85.9% growth in Molecular Profiling services** due to higher ASPs and increased clinical case volume, while operating expenses rose due to IPO-related stock-based compensation Revenue Comparison - Q2 2025 vs Q2 2024 (in thousands) | Revenue Stream | Q2 2025 | Q2 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Molecular profiling services | $162,924 | $87,656 | $75,268 | 85.9% | | Pharma research and development services | $18,474 | $12,393 | $6,081 | 49.1% | | **Total revenue** | **$181,398** | **$100,049** | **$81,349** | **81.3%** | - Molecular Profiling revenue growth was driven by **higher MI Profile ASP (+$50.3 million)**, **increased MI Profile volume (+$14.3 million)**, and **Caris Assure volume and ASP growth (+$10.7 million)**[234](index=234&type=chunk) - General and administrative expenses increased by **$23.3 million (56.7%)** in Q2 2025, primarily due to a **$20.3 million increase in IPO-related stock-based compensation**[242](index=242&type=chunk) [Liquidity and Capital Resources](index=72&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held **$718.9 million in cash and equivalents**, with IPO proceeds and existing capital expected to fund operations for at least the next 12 months, alongside **$400 million in outstanding term loan debt** maturing in 2028 - As of June 30, 2025, the company had **$718.9 million in cash and cash equivalents** and an **accumulated deficit of $2.7 billion**[280](index=280&type=chunk)[281](index=281&type=chunk) - Net cash provided by financing activities for the first six months of 2025 was **$682.7 million**, primarily from **IPO net proceeds ($528.5 million)** and pre-IPO financing[288](index=288&type=chunk) - The company has a **$400.0 million term loan** due January 2028, with an interest rate of **10.8%** as of June 30, 2025[290](index=290&type=chunk)[292](index=292&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=77&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks include interest rate risk on its **$400 million variable-rate debt**, where a **100 basis point increase** would raise annual interest expense by **$4.0 million**, while foreign currency and inflation risks are currently not significant - The company faces interest rate risk on its **$400.0 million variable-rate debt**, where a **100 basis point increase** would raise annual interest expense by **$4.0 million**[312](index=312&type=chunk) - Foreign currency risk is minimal as substantially all revenue is generated in the United States[314](index=314&type=chunk) [Item 4. Controls and Procedures](index=78&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective as of June 30, 2025, due to a material weakness in internal control over financial reporting, specifically a lack of qualified accounting resources, with remediation efforts underway - Disclosure controls and procedures were **not effective** as of June 30, 2025, due to a material weakness in internal control over financial reporting[317](index=317&type=chunk) - The material weakness stems from insufficient qualified accounting resources with technical expertise for complex transactions[317](index=317&type=chunk) - Remediation efforts include hiring experienced accounting and finance personnel and implementing enhanced review controls[319](index=319&type=chunk) [Part II - Other Information](index=81&type=section&id=Part%20II%20-%20Other%20Information) [Item 1. Legal Proceedings](index=81&type=section&id=Item%201.%20Legal%20Proceedings) In March 2025, the company received a Civil Investigative Demand from the U.S. Department of Justice regarding a False Claims Act investigation into Medicare's 14-day rule compliance, with the outcome currently uncertain - In March 2025, the company received a Civil Investigative Demand from the U.S. Department of Justice for a False Claims Act investigation[322](index=322&type=chunk) - The investigation focuses on compliance with Medicare's "14-day rule" for date of service[322](index=322&type=chunk) [Item 1A. Risk Factors](index=81&type=section&id=Item%201A.%20Risk%20Factors) This section details significant risks, including intense competition, a history of substantial losses, reliance on product market acceptance, uncertain third-party payer reimbursement, potential LDT regulatory changes, supply chain dependency, cybersecurity threats, significant indebtedness, CEO voting power concentration, and internal control weaknesses - The company has a history of significant losses, with a **net loss of $174.4 million** for the first six months of 2025 and an **accumulated deficit of $2.7 billion** as of June 30, 2025[332](index=332&type=chunk) - Uncertainty of coverage and reimbursement from third-party payers, including Medicare, poses a significant commercial risk[360](index=360&type=chunk) - Reliance on **Illumina** as the sole supplier for NGS instruments and reagents presents a significant supply chain risk[385](index=385&type=chunk) - The Founder, Chairman, and CEO, David D. Halbert, beneficially owns approximately **44.1% of outstanding common stock**, significantly influencing shareholder matters[646](index=646&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=176&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details unregistered equity sales, including **$30.0 million in convertible notes** and preferred stock issued in April 2025 that converted to common stock upon the IPO, and the use of **$519.5 million net proceeds** from the June 2025 IPO - In Q2 2025, the company issued convertible notes, Series E & F Preferred Stock, and warrants in unregistered transactions, all converting to common stock upon the IPO[685](index=685&type=chunk)[692](index=692&type=chunk) - The June 2025 IPO generated **$519.5 million in net proceeds** after deducting discounts and expenses[687](index=687&type=chunk) [Item 5. Other Information](index=179&type=section&id=Item%205.%20Other%20Information) On August 8, 2025, Caris MPI, Inc. extended its Phoenix, Arizona clinical laboratory lease until August 31, 2031, with no Rule 10b5-1 trading arrangements adopted or terminated by directors or officers during the quarter - On August 8, 2025, the company extended the lease for its Phoenix, Arizona clinical laboratory until **August 31, 2031**[695](index=695&type=chunk)

[Ampco-Pittsburgh Corporation Q2 2025 Earnings Release](index=1&type=section&id=Ampco-Pittsburgh%20Corporation%20Q2%202025%20Earnings%20Release) [Financial Performance Summary](index=1&type=section&id=Financial%20Performance%20Summary) Ampco-Pittsburgh reported Q2 2025 net sales of $113.1 million, swinging to an operating and net loss primarily due to a $6.8 million U.K. exit charge [Overall Results (Q2 & H1 2025)](index=1&type=section&id=Overall%20Results%20%28Q2%20%26%20H1%202025%29) The company reported a slight increase in Q2 2025 net sales but swung to an operating and net loss, primarily due to a U.K. exit charge | Financial Metric | Three Months Ended June 30, 2025 ($ in millions) | Three Months Ended June 30, 2024 ($ in millions) | Six Months Ended June 30, 2025 ($ in millions) | Six Months Ended June 30, 2024 ($ in millions) | | :--- | :--- | :--- | :--- | :--- | | Net Sales | $113.1 | $111.0 | $217.4 | $221.2 | | (Loss) Income from Operations | ($3.1) | $5.0 | $0.8 | $5.1 | | Net (Loss) Income Attributable to Ampco-Pittsburgh | ($7.3) | $2.0 | ($6.2) | ($0.7) | | Diluted (Loss) Earnings Per Share | ($0.36) | $0.10 | ($0.31) | ($0.04) | - The Q2 2025 operating loss of **$3.1 million** was primarily driven by **$6.8 million** in costs associated with the exit of its U.K. cast roll operations[3](index=3&type=chunk) - Higher sales of forged engineered products and favorable foreign exchange translation were offset by weaker mill roll sales, while Air and Liquid Processing sales remained stable year-over-year[2](index=2&type=chunk) [Adjusted EBITDA](index=1&type=section&id=Adjusted%20EBITDA) Adjusted EBITDA declined in Q2 2025 due to lower FCEP margins but improved year-to-date from ALP segment profitability | Period | Adjusted EBITDA ($ in millions) | Change from Prior Year ($ in millions) | | :--- | :--- | :--- | | Q2 2025 | $8.0 | -$2.1 | | H1 2025 | $16.8 | +$1.6 | - The decline in Q2 Adjusted EBITDA was attributed to lower margins in the Forged and Cast Engineered Products (FCEP) segment, which suffered from higher manufacturing costs, a weaker sales mix, and lower cost absorption[4](index=4&type=chunk) - The year-to-date improvement in Adjusted EBITDA was primarily due to improved profitability in the Air and Liquid Processing (ALP) segment[4](index=4&type=chunk) [Management Commentary and Outlook](index=1&type=section&id=Management%20Commentary%20and%20Outlook) Management noted Q2 volatility from U.S. tariffs impacting results and backlog, expecting improvement in 2026 post-U.K. exit - CEO Brett McBrayer stated that volatility from U.S. tariff actions negatively impacted results and the order book in Q2[5](index=5&type=chunk) - Backlog in the Forged and Cast Engineered Products segment declined **9%** from March 31, 2025, as customers paused orders amid tariff uncertainty[5](index=5&type=chunk) - The company expects an improved environment in 2026 following the U.K. exit and greater clarity on trade policy[6](index=6&type=chunk) [Strategic Business Updates](index=1&type=section&id=Strategic%20Business%20Updates) The company is exiting its U.K. cast roll operations, incurring **$6.8 million** in Q2 2025 costs, expecting to improve annual operating income by at least **$5 million** [U.K. Cast Roll Operations Exit](index=1&type=section&id=U.K.%20Cast%20Roll%20Operations%20Exit) The company recorded **$6.8 million** in Q2 2025 costs to exit its U.K. cast roll operations, anticipating at least **$5 million** annual earnings improvement - In Q2 2025, the company recorded expenses of **$6.8 million** for severance, accelerated depreciation, and other costs to exit its U.K. cast roll operations[3](index=3&type=chunk)[5](index=5&type=chunk) - The exit is expected to improve annual earnings by at least **$5 million**[5](index=5&type=chunk)[6](index=6&type=chunk) - The net loss for Q2 and H1 2025 includes the **$6.8 million** charge, which equates to **$0.34 per share**[9](index=9&type=chunk) [Segment Performance](index=1&type=section&id=Segment%20Performance) FCEP segment profitability declined in Q2 2025 due to higher costs and weaker sales mix, while ALP segment profitability improved from a better sales mix [Forged and Cast Engineered Products (FCEP)](index=1&type=section&id=Forged%20and%20Cast%20Engineered%20Products%20%28FCEP%29) FCEP segment margins were negatively impacted by higher manufacturing costs, a weaker sales mix, and lower cost absorption - FCEP segment margins were negatively affected by higher manufacturing costs relative to pricing, a weaker sales mix, and lower manufacturing cost absorption[4](index=4&type=chunk) | FCEP Segment | Q2 2025 ($ in millions) | Q2 2024 ($ in millions) | | :--- | :--- | :--- | | Net Sales | $77.9 | $75.7 | | Adjusted Income from Operations | $6.8 | $9.8 | | Adjusted Margin from Operations | 11.16% | 12.96% | [Air and Liquid Processing (ALP)](index=1&type=section&id=Air%20and%20Liquid%20Processing%20%28ALP%29) The ALP segment's profitability improved primarily due to a better sales mix, despite a slight decrease in adjusted margin - The ALP segment's profitability improved primarily due to a better sales mix[4](index=4&type=chunk) | ALP Segment | Q2 2025 ($ in millions) | Q2 2024 ($ in millions) | | :--- | :--- | :--- | | Net Sales | $35.2 | $35.3 | | Adjusted Income from Operations | $3.9 | $3.4 | | Adjusted Margin from Operations | 8.68% | 9.69% | [Financial Statements and Reconciliations](index=5&type=section&id=Financial%20Statements%20and%20Reconciliations) Detailed financial tables present Q2 2025 consolidated net loss of **$7.3 million** and reconciliations from GAAP to non-GAAP measures, including Adjusted EBITDA [Financial Summary (Consolidated)](index=5&type=section&id=Financial%20Summary%20%28Consolidated%29) The consolidated financial summary shows a Q2 2025 net loss of **$7.3 million**, a significant shift from prior year net income Consolidated Financial Summary (in thousands) | Line Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Total net sales | $113,104 | $110,988 | | (Loss) income from operations | $(3,078) | $5,043 | | Net (loss) income attributable to Ampco Pittsburgh | $(7,335) | $2,012 | | Diluted Net (loss) income per share | $(0.36) | $0.10 | [Reconciliation of Net Income to Adjusted EBITDA](index=6&type=section&id=Reconciliation%20of%20Net%20Income%20to%20Adjusted%20EBITDA) This section reconciles GAAP net loss to Adjusted EBITDA, detailing adjustments for interest, taxes, depreciation, and exit costs Q2 Adjusted EBITDA Reconciliation (in thousands) | Line Item | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Net (loss) income (GAAP) | $(6,720) | $2,552 | | Adjustments: | | | | Interest expense | $2,825 | $3,017 | | Other income – net | $225 | $(1,389) | | Income tax provision | $592 | $863 | | Depreciation and amortization | $5,368 | $4,698 | | Severance and other exit costs | $6,096 | $0 | | Employee retention credits | $(735) | $0 | | Stock-based compensation | $332 | $388 | | **EBITDA, as adjusted (Non-GAAP)** | **$7,983** | **$10,129** | [Reconciliation of Income from Operations to Adjusted Income from Operations (by Segment)](index=7&type=section&id=Reconciliation%20of%20Income%20from%20Operations%20to%20Adjusted%20Income%20from%20Operations%20%28by%20Segment%29) This reconciliation details segment-level adjustments from GAAP income from operations to adjusted income from operations Q2 Adjusted Income from Operations Reconciliation (in thousands) | Segment | (Loss) Income from Operations (GAAP) | Adjustments | Income from Operations, as adjusted (Non-GAAP) | | :--- | :--- | :--- | :--- | | FCEP | $(3,963) | $10,724 | $6,761 | | ALP | $3,922 | $(279) | $3,927 | | Corporate | $(3,037) | $332 | $(2,705) | | **Consolidated** | **$(3,078)** | **$11,061** | **$7,983** | [Supplementary Information](index=2&type=section&id=Supplementary%20Information) This section provides investor details, including conference call logistics, corporate overview, forward-looking statements disclaimer, and non-GAAP financial measures explanation [Conference Call Information](index=2&type=section&id=Conference%20Call%20Information) Details for the Q2 2025 financial results conference call are provided for investor access - A conference call to discuss Q2 2025 financial results was scheduled for Wednesday, August 13, 2025, at **10:30 a.m. Eastern Time (ET)**[10](index=10&type=chunk) [Non-GAAP Financial Measures Explanation](index=3&type=section&id=Non-GAAP%20Financial%20Measures%20Explanation) This section explains the use of non-GAAP measures like Adjusted EBITDA to evaluate operating performance and identify trends - The company uses non-GAAP measures like Adjusted EBITDA and Adjusted Income from Operations to help management and investors evaluate operating performance and identify underlying business trends[18](index=18&type=chunk)[19](index=19&type=chunk) - For Q2 2025, key adjustments from GAAP measures include the exclusion of severance and other exit costs related to the U.K. operations and the inclusion of employee-retention credits[17](index=17&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) The report contains forward-looking statements subject to various risks, including economic downturns and geopolitical conflicts - The report contains forward-looking statements regarding future performance, which are subject to various risks and uncertainties, including economic downturns, restructuring challenges, commodity price increases, and geopolitical conflicts[15](index=15&type=chunk)

For the quarterly period ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41282 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SUNSHINE BIOPHARMA INC. (Exact name of registrant as specified in its charter) (State of other jurisdiction of incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42367 KinderCare Learning Companies, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 87-1653366 | | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission File Number: 001-41863 SIGNING DAY SPORTS, INC. (Exact name of registrant as specified in its charter) Delaware 87-279 ...

Exhibit 99.1 Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update $12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction CRANFORD, N.J., August 12, 2025 -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late- stage biopharmaceutical company dedicated to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission File Number: 001-42539 FIFTH ERA ACQUISITION CORP I (Exact name of registrant as specified in its charter) | Cayman Islands | 36-5108801 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | PO Box 1093 Boundary Hall | | | Cricket Square, Grand Cayman | | Cayman Islands KY1-1102 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42539 FIFTH ERA ACQUISITION CORP I (Exact name of registrant as specified in its charter) | Cayman Islands | 36-5108801 | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-42699 Blue Acquisition Corp. | | Trading | Name of each exchange on which | | --- | --- | --- | | Title of each class | Symbol( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-42699 Securities registered pursuant to Section 12(b) of the Act: Blue Acquisition Corp. (Exact name of registrant as specified ...